Capecitabine and hand-foot syndrome

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 159-169

  Saif, Muhammad Wasif ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b P and S 3 401 ^*  (United States)

Author keywords

5 fluorouracil; capecitabine; dihydropyrimidine dehydrogenase; hand foot syndrome; thymidine phosphorylase

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYTARABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PROSTAGLANDIN SYNTHASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYMIDINE PHOSPHORYLASE;

ADJUVANT THERAPY; ADULT; AFRICAN AMERICAN; AGED; BLISTER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DESQUAMATION; DIFFERENTIAL DIAGNOSIS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSESTHESIA; EDEMA; ERYTHEMA; ETHNIC DIFFERENCE; GASTRECTOMY; GASTROJEJUNOSTOMY; HAND FOOT SYNDROME; HAND PARESTHESIA; HUMAN; INCIDENCE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS ADENOCARCINOMA; PATHOGENESIS; PATIENT COMPLIANCE; RECTUM CANCER; REVIEW; SKIN BURNING SENSATION; SKIN SWELLING; SKIN TINGLING; SKIN TOXICITY; STOMACH ADENOCARCINOMA; SWELLING;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CONTINENTAL POPULATION GROUPS; DEOXYCYTIDINE; DIAGNOSIS, DIFFERENTIAL; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS;

EID: 79952321958     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.546342     Document Type: Review

References (65)

1. Xeloda (capecitabine) [package insert]: Nutley, NJ: Roche Pharmaceuticals; April 2006
2. Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol 2007;5:337-43 (Pubitemid 350055014)
3. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;10:3537-41
4. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93 (Pubitemid 29075232)
5. Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-73
6. de Vries EG, Greidanus J, Mulder NH, et al. A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. J Clin Oncol 1987;5:1445-51 (Pubitemid 18049880)
7. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995;131:202-6
8. Beldner M, Jacobson M, Burges GE, et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12:1178-82 (Pubitemid 350106348)
9. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-11
10. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16:549-57 (Pubitemid 40613320)
11. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102-9 (Pubitemid 350003057)
12. Scheithauer W, McKendrick J, Begbie S, et al. X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-43
13. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704 (Pubitemid 41007824)
14. Cassidy J, Twelves C, Van Cutsem E, et al. Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75
15. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16 (Pubitemid 34983220)
16. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27 (Pubitemid 34983221)
17. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002;20:3-10 (Pubitemid 34151055)
18. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002;16(12 Suppl 14):31-7
19. Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004;18:1161-8, 1173
20. Walker IR, Wilson WE, Sauder DN, et al. Cytarabine-induced palmar-plantar erythema. Arch Dermatol 1985;121:1240-1
21. Silver FS, Espinoza LR, Hartmann RC. Acral erythema and hydroxyurea. Ann Intern Med 1983;98(5 pt 1):675 (Pubitemid 13091191)
22. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001;26:141-8 (Pubitemid 32275705)
23. Fukamachi S, Nakamura M, Tokura Y. Cisplatin-induced acral erythema. Eur J Dermatol 2009;19:171-2
24. Pagliuca A, Kaczmarski R, Mufti GJ. Palmar-plantar erythema associated with combination chemotherapy. Postgrad Med J 1990;66:242-3 (Pubitemid 20083089)
25. Feizy V, Namazi MR, Barikbin B, Ehsani A. Methotrexate-induced acral erythema with bullous reaction. Dermatol Online J 2003;9:14
26. Hoff PM, Valero V, Ibrahim N, et al. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998;82:965-9 (Pubitemid 28104178)
27. Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008;112:1625-31 (Pubitemid 351441177)
28. Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol 2009;2009:849051
29. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-71
30. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):S31-40
31. Saif MW, Juneja V, Black G, et al. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Support Cancer Ther 2007;4:211-18
32. Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006;6:219-23 (Pubitemid 44596772)
33. Saif MW, Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Cutan Ocul Toxicol 2008;27:311-15
34. Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 2004;73:101-6 (Pubitemid 38326411)
35. Vickers MM, Easaw JC. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. J Gastrointest Cancer 2008;39:141-3
36. Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5 (Pubitemid 44497265)
37. Milano G, Etienne-Grimaldi MC, Mari M, et al. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;66:88-95 (Pubitemid 351822156)
38. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008;14:8-13
39. Asgari MM, Haggerty JG, McNiff JM, et al. Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol 1999;26:287-94 (Pubitemid 29373926)
40. Fischel JL, Formento P, Ciccolini J, et al. Lack of contribution of dihydrofluorouracil and alpha-fluorobeta-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs 2004;15:969-74 (Pubitemid 39557484)
41. Temmink OH, de Bruin M, Turksma AW, et al. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007;39:565-75 (Pubitemid 46096794)
42. Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 2006;5:359-62
43. Yamashita K, Yada H, Ariyoshi T. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. J Toxicol Sci 2004;29:155-66 (Pubitemid 38855928)
44. Okeda R, Shibutani M, Matsuo T, et al. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol 1990;81:66-73 (Pubitemid 20377478)
45. Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999;26:753-62
46. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333-8 (Pubitemid 23207988)
47. Hu ZP, Yang XX, Chan SY, et al. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006;216:225-37
48. Xue H, Field CJ, Sawyer MB, et al. Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy. Br J Cancer 2009;100:1581-8
49. Melo ML, Brito GA, Soares RC, et al. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 2008;61:775-84 (Pubitemid 351302033)
50. Cao S, Black JD, Troutt AB, Rustum YM. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 1998;58:3270-4 (Pubitemid 28371064)
51. Disel U, Gurkut O, Abali H, et al. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol 2010. [Epub ahead of print]
52. Lacouture ME. Dermatologic toxicities associated with targeted therapies. Cancer management: a multidisciplinary approach. 11 edition. 2008; 15 May 2009. Available from: http://www.cancernetwork.com/cancermanagement-11/coloratlas3/ article/10165/1414174#
53. Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303-6 (Pubitemid 29402199)
54. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995;13:2851-5
55. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57-63 (Pubitemid 20087245)
56. Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990;26:449-52 (Pubitemid 20333750)
57. Saif MW, Eloubeidi MA, Russo S, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005;23:8679-87 (Pubitemid 46211511)
58. Yoshimoto N, Yamashita T, Fujita T, et al. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer 2009. [Epub ahead of print]
59. Kang YK, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010;28(24):3824-9
60. Kohne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008;19:920-6 (Pubitemid 351627308)
61. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86 (Pubitemid 350086481)
62. Kingsley EC. 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994;120:813 (Pubitemid 24125309)
63. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
64. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20(4):666-73
65. Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20(9):1529-34